MBX MBX Biosciences, Inc.companySEC Filings & Insider Trading Activity 2026
Latest MBX Biosciences, Inc. (MBX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 12, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for MBX Biosciences, Inc. (MBX) (SEC CIK 1776111), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Clinical-stage biopharma developing novel precision peptide therapies for endocrine and metabolic disorders via proprietary PEP™ platform
- • New emphasis on once-weekly canvuparatide for chronic hypoparathyroidism with positive Phase 2 data; Phase 3 trial to start Q3 2026
Risk Factors
- • FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
- • Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations
Management Discussion & Analysis
- • Net loss $87.0M in 2025 vs $61.9M in 2024; operating expenses rose $29.9M to $98.1M
- • R&D expenses $79.2M (29.7% increase) driven by canvuparatide ($37.2M, up $15.6M) and MBX 4291 ($12.7M, up $1.9M); imapextide decreased $7.4M
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Full-year 2025 financial results announced March 12, 2026
- • Details and key figures contained in Exhibit 99.1 press release — primary source for revenue, cash, and pipeline spend data
Item 7.01: Regulation FD Disclosure
- • Successful End-of-Phase 2 FDA meeting completed for canvuparatide, a once-weekly treatment for hypoparathyroidism — a key regulatory de-risking milestone
- • FDA alignment on Phase 3 design signals clearer path to pivotal trial and potential approval for rare endocrine disorder
Item 8.01: Other Events
- • FDA EOP2 meeting completed March 9, 2026 — Phase 3 trial for canvuparatide (chronic hypoparathyroidism) cleared to launch Q3 2026
- • Trial design: ~160 patients, 3:1 randomization (canvuparatide vs placebo), 600 µg fixed dose, 26-week primary endpoint assessment plus open-label extension
Item 1.01: Entry into a Material Definitive Agreement
- • New lab/office lease signed Feb 24, 2026 in Burlington, MA — 13,642 sq ft; occupancy expected May 1, 2026
- • Rent-free for first 5 months post-commencement; base rent ~$68,200/month starting ~Oct 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CFO Richard Bartram resigning effective March 15, 2026; receives $13,400 COBRA lump sum plus severance per existing employment agreement
- • Departure confirmed not due to dispute with company or auditors — reduces concern over financial reporting integrity issues
Annual Reports Archive10-K
AI-powered analysis of MBX Biosciences, Inc. (MBX) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of MBX Biosciences, Inc. (MBX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | — | -$35.3M | -$68.2M | -$98.1M |
| Net Income | — | -$32.6M | -$61.9M | -$87.0M |
| Balance Sheet | ||||
| Total Assets | — | $84.2M | $268.5M | $385.1M |
| Equity | -$42.6M | -$72.5M | $257.4M | $369.2M |
| ROE | — | 44.9% | -24.1% | -23.6% |
Source: XBRL financial data from MBX Biosciences, Inc. (MBX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Mar 12, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 12, 2026 | — | Analysis | — |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Feb 27, 2026 | — | Analysis | — |
8-K | Feb 5, 2026 | — | — | |
8-K | Jan 22, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 17, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — |
Frequently Asked Questions
What are the latest MBX SEC filings in 2026?
MBX Biosciences, Inc. (MBX) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did MBX file its most recent 10-K annual report?
MBX Biosciences, Inc. (MBX) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view MBX 10-Q quarterly reports?
MBX Biosciences, Inc. (MBX)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every MBX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has MBX filed recently?
MBX Biosciences, Inc. (MBX)'s most recent 8-K was filed on March 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find MBX insider trading activity (Form 4)?
SignalX aggregates every MBX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does MBX file with the SEC?
MBX Biosciences, Inc. (MBX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MBX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for MBX Biosciences, Inc. (MBX).
What is MBX's SEC CIK number?
MBX Biosciences, Inc. (MBX)'s SEC CIK (Central Index Key) number is 1776111. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1776111 to look up all MBX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find MBX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from MBX Biosciences, Inc. (MBX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of MBX Biosciences, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 12+ filings.